The paper presents a comparative study of the clinical and economic effectiveness of hardware ileoanal anastomosis performed with a Johnson circular stapler in the surgical treatment of nonspecific ulcerative colitis (UC). The data of 100 patients included in the period 2015-2024 were analyzed: the main group - 35 patients operated on using a stapler , and the comparative group - 65 patients in whom the anastomosis was formed by hand suture. It was shown that the use of the device significantly reduced the duration of the operation (142 ± 5 versus 175 ± 6 min), decreased the volume of intraoperative blood loss (480 ± 20 versus 610 ± 25 ml) and reduced the incidence of postoperative complications (8.6% versus 26.2%; p < 0.05 ). The average hospital stay decreased to 9.3 ± 0.5 days versus 12.1 ± 0.6 days, and the total cost of treatment per patient decreased by approximately 10–12% (USD 2,950 ± 100 versus USD 3,300 ± 120). The results indicate that the stapler technique for ileoanal reservoir formation not only improves immediate surgical outcomes, but also provides significant economic benefits by reducing the length of hospital stay and reducing the costs of treating complications. Thus, the Johnson apparatus can be considered as a preferred method for radical interventions in patients with UC .

nonspecific ulcerative colitis; Johnson apparatus; ileoanal anastomosis; stapler technique; clinical and economic efficiency; postoperative complications; colproctectomy .

Abraham C., Cho JH Inflammatory bowel disease // N. Engl. J. Med. – 2009. – Vol. 361, No. 21. – P. 2066–2078.

Farraye FA, Moss AC, Shaheen NJ, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults // Am. J. Gastroenterol . – 2019. – Vol. 114, No. 3. – P. 384–413.

Feuerstein JD, Moss AC, Farraye FA Ulcerative colitis: epidemiology, diagnosis, and management // Mayo Clin . Proc. – 2019. – Vol. 94, No. 7. – P. 1323–1343.

Fujiwara D., Maeda Y., Kajii E. et al. Mucosal healing in clinical practice: how useful is fecal calprotectin ? // Inflamm . Bowel Dis. – 2013. – Vol. 19, No. 6. – P. 1437–1444.

Gros B., Kaplan GG Ulcerative colitis in adults: a review // JAMA. – 2023. – Vol. 330, No. 10. – P. 951–965.

Harbord M., Eliakim R., Bettenworth D., et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management // J. Crohns Colitis. – 2017. – Vol. 11, No. 7. – P. 769–784.

Jess T., Gamborg M., Munkholm P., Sørensen TI Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies // Am. J. Gastroenterol . – 2007. – Vol. 102, No. 3. – P. 609–617.

Kaser A., Zeissig S., Blumberg RS Inflammatory bowel disease // Annu . Rev. Immunol . – 2010. – Vol. 28. – P. 573–621.

Kornbluth A., Sachar DB Ulcerative colitis practice guidelines in adults: ACG, ECCO, and World Gastroenterology Organization perspectives // Mayo Clin . Proc. – 2010. – Vol. 85, Suppl. – S1–S42.

Kornbluth A., Sachar DB Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, 2010 update // Am. J. Gastroenterol . – 2010. – Vol. 105, No. 3. – P. 501–523.

Lamb CA, Kennedy NA, Raine T., et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults // Gut. – 2019. – Vol. 68, Suppl. 3. – P. s1–s106.

Le Berre C., Honap S., Peyrin-Biroulet L. Ulcerative colitis // Lancet. – 2023. – Vol. 402, No. 10401. – P. 571–584.

Lyukmayev V. Yu ., Shushera VE, Orlova MA et al. Ulcerative colitis (review) // Gastroenterol . Hepatol . Polymed . – 2021. – Vol. 18, No. 3. – P. 52–59. ( on ( Russian language )

Narula N., Peerani F., Kushnir V. et al. Fecal microbiota transplant for ulcerative colitis – a systematic review and meta-analysis // Inflamm . Bowel Dis. – 2017. – Vol. 23, No. 10. – P. 1702–1709.

Panaccione R., Ghosh S., Middleton S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis // Gastroenterology. – 2014. – Vol. 146, No. 2. – P. 392–400.

Porter R.J., Kalla R., Ho G.-T. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis // F1000Res. – 2020. – Vol. 9. – Article 294.

Pravda J. Evidence-based pathogenesis and treatment of ulcerative colitis: A causal role for colonic epithelial hydrogen peroxide // World J. Gastroenterol . – 2022. – Vol. 28, No. 31. – P. 4263–4298.

Rafiee P., Singh S., Sandborn W.J., et al. Anti-integrin therapies for inflammatory bowel disease // Gastroenterology. – 2013. – Vol. 145, No. 6. – P. 1687–1698.

Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults // Am. J. Gastroenterol . – 2019. – Vol. 114, No. 4. – P. 384–413.

Rutgeerts P., Sandborn W.J., Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis // N. Engl. J. Med. – 2005. – Vol. 353, No. 23. – P. 2462–2476.

Sandborn W.J., Feagan BG, Rutgeerts P., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis // Gastroenterology. – 2012. – Vol. 142, No. 2. – P. 257–265.

Segal JP, LeBlanc J.-F., Hart AL Ulcerative colitis: an update // Clin . Med. ( Lond .). – 2021. – Vol. 21, No. 2. – P. 135–139.

Travis SP, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management // J. Crohns Colitis. – 2008. – Vol. 2, No. 1. – P. 24–62.

Ungaro R., Mehandru S., Allen PB, et al. Ulcerative colitis // Lancet. – 2017. – Vol. 389, No. 10080. – P. 1756–1770.